Author pages are created from data sourced from our academic publisher partnerships and public sources.
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
- K. Yonkers, C. Brown, T. Pearlstein, M. Foegh, Carole Sampson-Landers, A. Rapkin
- Obstetrics and gynecology
- 1 September 2005
Objective: To compare the efficacy of a new low-dose oral contraceptive pill (OCP) formulation with placebo in reducing symptoms of premenstrual dysphoric disorder. Methods: This multicenter,… Expand
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
- E. Freeman, R. Kroll, +6 authors M. Foegh
- Journal of women's health & gender-based medicine
- 1 July 2001
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). This is the first trial of a unique oral contraceptive containing a combination of drospirenone (DRSP, 3 mg)… Expand
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
Objective:The purpose of this multicenter, double-blind, randomized, parallel-group study was to determine the effect of thirteen 28-day cycles of drospirenone combined with estradiol, compared with… Expand
Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and…
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
BACKGROUND AG200-15 Agile Patch (AP) is a novel 7-day contraceptive patch providing ethinyl estradiol (EE) exposure comparable to low-dose combination oral contraceptives. This study determined… Expand
Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel.
BACKGROUND The effect of obesity on ovarian follicular suppression in women using low-estrogen dose contraceptive patches has not been determined. STUDY DESIGN A Phase II, parallel-group,… Expand
A Routine Source of Human Peritoneal Macrophages
- Y. Maddox, M. Foegh, B. Zeligs, M. Zmudka, J. Bellanti, P. Ramwell
- Scandinavian journal of immunology
- 1 January 1984
The routine availability of nucleated human cells for experimental use is limited in the absence of venipuncture. In this paper we have demonstrated that macrophages may he harvested routinely from… Expand
Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model.
BACKGROUND In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with… Expand
Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
BACKGROUND The oral contraceptive ethinyl estradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) contains a progestin component that possesses potassium-sparing diuretic activity similar to spironolactone. We… Expand